Galmed Pharmaceuticals Ltd (GLMD)

Dec 05, 2024

Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria

Dec 05, 2024

Dec 05, 2024

Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa

Dec 05, 2024

Nov 26, 2024

Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa

Nov 26, 2024

Nov 26, 2024

Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria

Nov 26, 2024

Nov 16, 2024

Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register

Nov 16, 2024

Nov 14, 2024

Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks

Nov 14, 2024

Nov 14, 2024

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024

Nov 12, 2024

Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia

Nov 12, 2024

Nov 11, 2024

500: Something went wrong - Investing.com Canada

Nov 11, 2024

Oct 21, 2024

Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks

Oct 21, 2024

Oct 11, 2024

Acyl CoA Desaturase Market Current Status and Future Prospects - IndiaPolitics.com

Oct 11, 2024

Oct 04, 2024

galmed pharmaceuticals ltd. Earnings dates - RTTNews

Oct 04, 2024

Oct 01, 2024

Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Above 50-Day Moving Average of $4.52 - Defense World

Oct 01, 2024

Oct 01, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN

Oct 01, 2024

Sep 26, 2024

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN

Sep 26, 2024

Sep 26, 2024

(GLMD) Long Term Investment Analysis - Stock Traders Daily

Sep 26, 2024

Sep 26, 2024

Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com Australia

Sep 26, 2024

Sep 25, 2024

Galmed reports positive results for Aramchol in NASH study - Investing.com India

Sep 25, 2024

Sep 25, 2024

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire

Sep 25, 2024

Sep 25, 2024

Post-Trade Analysis: Galmed Pharmaceuticals Ltd (GLMD) Slides -13.90, Closing at 8.05 - The Dwinnex

Sep 25, 2024

Sep 24, 2024

Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News

Sep 24, 2024

Sep 23, 2024

Understanding GLMD stock ratios for better investment decisions - US Post News

Sep 23, 2024

Sep 23, 2024

GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Sep 23, 2024

Sep 23, 2024

Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward - Stocks Telegraph

Sep 23, 2024

Sep 20, 2024

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire

Sep 20, 2024

Sep 20, 2024

Galmed Pharmaceuticals Calls for Capital Increase Vote - TipRanks

Sep 20, 2024

Sep 19, 2024

Galmed expands drug development to cancer and heart diseases - Investing.com

Sep 19, 2024

Sep 19, 2024

Galmed surges on plans to expand into cancer and heart disease drug development - XM

Sep 19, 2024

Sep 19, 2024

Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why - Benzinga

Sep 19, 2024

Sep 19, 2024

Market Insights: Galmed Pharmaceuticals Ltd (GLMD)’s Notable Drop of -54.30, Closing at 6.90 - The Dwinnex

Sep 19, 2024

Sep 19, 2024

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - PR Newswire

Sep 19, 2024

Sep 18, 2024

B. Riley FBR Downgrades Galmed Pharmaceuticals Ltd (GLMD) to a Neutral from a Buy - Knox Daily

Sep 18, 2024

Sep 18, 2024

Galmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price - MarketWatch

Sep 18, 2024

Sep 18, 2024

US Stocks Mixed; General Mills Posts Upbeat Earnings - Benzinga

Sep 18, 2024

Sep 18, 2024

A new trading data show Galmed Pharmaceuticals Ltd (GLMD) is showing positive returns. - SETE News

Sep 18, 2024

Sep 18, 2024

Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze - TipRanks

Sep 18, 2024

Sep 17, 2024

Those who invested in Neuren Pharmaceuticals (ASX:NEU) three years ago are up 576% - Yahoo Finance

Sep 17, 2024

Sep 17, 2024

Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat

Sep 17, 2024

Sep 17, 2024

Gold Edges Lower; US Homebuilder Sentiment Rises For September - Benzinga

Sep 17, 2024

Sep 17, 2024

Galmed Pharmaceuticals Surges After Regaining Nasdaq Compliance - MarketWatch

Sep 17, 2024

Sep 17, 2024

Galmed Pharmaceuticals Ltd’s Banking’s 100-Day Moving Average at 4.01: Will the Stock Break Through? - The InvestChronicle

Sep 17, 2024

Sep 17, 2024

Stock Market news: Galmed Pharmaceuticals soars 283%, Intel up 3.49%, while Tupperware plunges 57% - Business Upturn

Sep 17, 2024

Sep 17, 2024

Express Scripts sues FTC and demands drug pricing report retraction - Yahoo! Voices

Sep 17, 2024

Sep 17, 2024

With its newest mac and cheese, Stouffer's expands beyond the freezer aisle to supermarket shelves - Yahoo! Voices

Sep 17, 2024

Sep 17, 2024

Merit Medical touts positive six-month data from WAVE trial - Yahoo! Voices

Sep 17, 2024

Sep 17, 2024

Lunds & Byerlys digitizes refrigeration compliance management - Yahoo! Voices

Sep 17, 2024